title: BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions.
authors.affiliation: Department of Radiation Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Wallach
authors.affiliation: Department of Medical Oncology, Bayer Hospital, Wayne, New Jersey.
authors.forename: Petra
authors.initials: P
authors.lastname: Rietschel
authors.affiliation: Department of Radiation Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Shalom
authors.initials: S
authors.lastname: Kalnicki
authors.affiliation: Department of Radiation Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York. Electronic address: jfox@montefiore.org.
authors.forename: Jana L
authors.initials: JL
authors.lastname: Fox
mesh_terms: D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000150:complications* / Q000556:secondary / Q000628:therapy; D059248:Chemoradiotherapy / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000150:complications* / Q000473:pathology / Q000628:therapy; D009059:Mouth Diseases / Q000209:etiology* / Q000628:therapy; D009361:Neoplasm Invasiveness; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012871:Skin Diseases / Q000209:etiology* / Q000628:therapy; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf